Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss. Promising alternative clinical uses of prostaglandin F2 α analogs: beyond the eyelashes. Safety and efficacy of bimatoprost for eyelash growth in postchemotherapy subjects. Periorbital changes associated with topical prostaglandins analogues in a Hispanic population. Rodríguez-Agramonte F, Jiménez JC, Montes JR.Management of hypotrichosis of the eyelashes: focus on bimatoprost. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study. Fagien S, Walt JG, Carruthers J, et al.

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial.

Brandt JD, VanDenburgh AM, Chen K, et al Bimatoprost Study Group.

A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Effect of age on the development of a latanoprost-induced increase in iris pigmentation. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

Wistrand PJ, Stjernschantz J, Olsson K.

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension.

Inoue K, Shiokawa M, Sugahara M, et al.

Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Stjernschantz JW, Albert DM, Hu D-N, et al.Prostaglandin-induced iridial pigmentation in primates. Clinical Dermatology: A Color Guide to Diagnosis and Treatment. one-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Higginbotham EJ, Schuman JS, Goldberg I, et al Bimatoprost Study Groups 1 and 2.Do cosmetics enhance female Caucasian facial attractiveness? Int J Cosmet Sci. Mulhern R, Fieldman G, Hussey T, et al.

Eye of the beholder 2 solution